Statement Regarding Sedia's Role in Novel SARS-CoV-2 Whole Genome Sequencing for Novel Variant Detection and Surveillance
From Dr. Clay Roscoe, Chief Medical Officer, Sedia Biosciences:
“Presently, SARS-CoV-2 variants from the UK, South Africa and Brazil have been identified in the U.S., along with several additional variants of interest or concern that have emerged domestically. Many of these variants have been shown to spread more easily and we continue to not fully understand how widely these variants have spread in-country, how the disease caused by these variants differs from other variants currently circulating, or how these variants may affect existing therapies, vaccines, and diagnostic tests. An affordable and accurate genomic surveillance service can assist with the detection and monitoring of novel variants and will be important in our ongoing response to the COVID-19 pandemic, here in the U.S. and globally”
How it works:
2. Complete the required documents for sample submission
3. We will send you a sample transfer kit
4. Once you receive the kit, transfer your samples
5. Clean the sample tubes and send in your samples
6. Data will be provided within 2-3 weeks of sample receipt
What you will receive:
1. All raw sequence files with intermediate files
2. Illumina Dragon software analysis and reports comparing your samples to known variants
contact our Customer Service Department at email@example.com
Advancing Access to Care Through Innovation
Sedia Biosciences' mission is to advance global access to healthcare by developing innovative disease surveillance and monitoring tools, expanding accessible point-of-care diagnostic testing into both technology-rich and resource-limited settings and providing cost-effective specimen collection devices.
OUR Products & Technologies
Enzyme immunoassays designed to distinguish recent HIV infections from long-term ones as a means to measure incidence of new HIV infections in populations. We are also developing assays that will target recent infections which have the highest risk of transmission, which pose the greatest risk to others, to enable aggressive treatment, follow-up and customized therapy.
Rapid cost-effective assays that provide diagnostic results from a variety of specimens, including whole and finger-stick blood, serum, plasma, oral fluid, urine and other clinical specimens. Most of our assays are focused on infectious diseases. However, we are developing rapid assays that identify other disease markers as well.
Devices intended to collect, stabilize and transport specimens from the point-of-care to the clinical laboratory. Designed to be cost effective, robust and to provide a high yield of usable analytes, such as DNA, proteins, antibodies, enzymes and other biomarkers. We also market low cost, easier-to-use alternatives to classical dried blood spot cards.
We have a variety of licensing and commercial partnership opportunities. Our technologies are available for licensing to third parties interesting in expanding their technology portfolios, developing improvements to their own technologies, or seeking custom solutions to technological challenges they may encounter. We are also experienced at commercializing third-party technologies for developers who are seeking to turn their prototypes into commercial products.